Profile: VC Forbion's Slootweg Sees Bigger And Better European Funds

Sander Slootweg, managing partner and co-founder of Forbion Capital Partners, talks venture capital trends, industrial changes to watch, deal making and challenges faced during his years investing in the life science industry in the latest instalment of Scrip's executive profile series.

SANDER SLOOTWEG
Sander Slootweg, Forbion Capital Partners

Before co-founding Forbion Capital Partners as a spin-out of ABN AMRO Capital Life Sciences in 2006, Slootweg was an investment director at ABN AMRO Capital Life Sciences. As Forbion's managing partner, Slootweg played a big role in selling BioVex Inc. to Amgen Inc. in 2011 for up to $1bn and the sale of Dezima Pharma BV, also to Amgen, in 2015 for around $1.55bn. He is currently on the board of Forbion portfolio companies Xention Discovery Ltd, Pulmagen Therapeutics Ltd, Oxyrane Ltd and Replimune Ltd.

Slootweg discussed with Scrip his experience in the venture capital business, and his thoughts about the direction of biotechnology investment.

More from Leadership

Executives On The Move: Fable Therapeutics Gains CMO From AstraZeneca

Recent moves in the industry include changes at the top at 32 Biosciences, plus new CEOs at Idorsia, Courage Therapeutics and Oncolytics Biotech.

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By 

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By 

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.